Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Pharma Equity Group: Status på selskabets tilgodehavende fra Portinho S.A.

By Claus ThestrupCEO, Sweden
Pharma Equity Group

Pharma Equity Group: Status på selskabets tilgodehavende fra Portinho S.A.

Selskabet udsendte i går en status på tidligere udmelding fra juni omkring tilgodehavende fra Portinho S.A. Pharma Equity Group venter nu at betalingen vil ske inden årets udgang. Samtidig starter selskabet en process for sikrer finansiering via eksistrende aktionærer. Selskabet sigter på en bridge finansiering.

Læs hele meddelelsen her: Portinho

Disclaimer:

HC Andersen Capital modtager betaling fra Pharma Equity Group for en Digital IR/Corporate Visibility abonnementsaftale. /Claus Thestrup kl. 08.30 d. 26/9-2023

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.